Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma

Table 6 Comparisons of chemotherapy side effects, case (%)

Side effect	Older group (n = 32)			Control group (n = 38)			P1 value
	I-IV	III	IV	I-IV	III	IV
Leukopenia	25 (78.1)	3 (9.3)	0	28 (73.7)	4 (10.5)	0	0.666
Anemia	24 (75.0)	2 (6.2)	0	27 (71.1)	2 (5.3)	0	0.900
Thrombocytopenia	23 (71.9)	1 (3.1)	0	27 (71.1)	1 (2.6)	0	0.940
Fever	2 (6.3)	0	0	3 (7.9)	0	0	1.000
Oral mucositis	13 (40.6)	0	0	14 (36.8)	0	0	0.746
Nausea/vomiting	10 (31.3)	0	0	11 (28.9)	0	0	0.834
Diarrhea	14 (43.8)	0	0	16 (42.1)	0	0	0.890
Fatigue	21 (65.6)	2 (6.3)	0	23 (60.5)	1 (2.6)	0	0.660
Sensory neuropathy	18 (56.3)	0	0	21 (55.3)	0	0	0.934
Liver function (ALT/AST)	4 (12.5)	0	0	3 (7.9)	0	0	0.810
Renal function (BUN/Cr)	1 (3.1)	0	0	0	0	0	-
Hand-foot syndrome	0	0	0	0	0	0	-
Myocardial ischemia	0	0	0	0	0	0	-
Anaphylaxis	0	0	0	0	0	0	-

¹P value for gradeI-IV between older group and control group. ALT: Alanine transaminase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; Cr: Creatine.